---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-261663"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:51:34.733789+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Karyopharm Q3 net loss $33.1M; XPOVIO revenue up 8.5%; SENTRY data March 2026

## Summary
- Total rev $44.0M ($38.8M Q3 2024); U.S. XPOVIO net product rev $32.0M (+8.5% vs $29.5M).
- Net loss $33.1M ($3.82/sh) vs $32.1M ($3.85/sh); operating loss improved 42% to $15.2M.
- Phase 3 SENTRY myelofibrosis trial enrollment complete (353 pts); top-line data due March 2026.
- Reaffirms FY2025 total rev guidance $140M-$155M, XPOVIO rev $110M-$120M; lowers expense guide to $235M-$245M.
- Cash $46.2M at Sep 30 (proforma ~$78M after Oct 8 financing); expects liquidity into Q2 2026.

## SEC filing metadata
- accession: 0001193125-25-261663
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312525261663/0001193125-25-261663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312525261663/kpti-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-261663
- JSON: https://secwatch.observer/filing/0001193125-25-261663.json
- Plain text: https://secwatch.observer/filing/0001193125-25-261663.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.